The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteri

Show simple item record

dc.contributor.author Draper, Lorraine A.
dc.contributor.author Cotter, Paul D.
dc.contributor.author Hill, Colin
dc.contributor.author Ross, R. Paul
dc.date.accessioned 2016-02-08T13:30:34Z
dc.date.available 2016-02-08T13:30:34Z
dc.date.issued 2013-09-26
dc.identifier.citation DRAPER, L. A., COTTER, P. D., HILL, C. & ROSS, R. P. 2013. The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria. BMC Microbiology, 13:212, 1-8. http://dx.doi.org/10.1186/1471-2180-13-212 en
dc.identifier.volume 13 en
dc.identifier.startpage 1 en
dc.identifier.endpage 8 en
dc.identifier.issn 1471-2180
dc.identifier.uri http://hdl.handle.net/10468/2264
dc.identifier.doi 10.1186/1471-2180-13-212
dc.description.abstract Background: The emergence of bacterial drug resistance encourages the re-evaluation of the potential of existing antimicrobials. Lantibiotics are post-translationally modified, ribosomally synthesised antimicrobial peptides with a broad spectrum antimicrobial activity. Here, we focussed on expanding the potential of lacticin 3147, one of the most studied lantibiotics and one which possesses potent activity against a wide range of Gram positive species including many nosocomial pathogens. More specifically, our aim was to investigate if lacticin 3147 activity could be enhanced when combined with a range of different clinical antibiotics. Results: Initial screening revealed that polymyxin B and polymyxin E (colistin) exhibited synergistic activity with lacticin 3147. Checkerboard assays were performed against a number of strains, including both Gram positive and Gram negative species. The resultant fractional inhibitory concentration (FIC) index values established that, while partial synergy was detected against Gram positive targets, synergy was obvious against Gram negative species, including Cronobacter and E. coli. Conclusions: Combining lacticin 3147 with low levels of a polymyxin could provide a means of broadening target specificity of the lantibiotic, while also reducing polymyxin use due to the lower concentrations required as a result of synergy. en
dc.description.sponsorship Science Foundation Ireland (Investigator Award 10/IN.1/B3027) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher BioMed Central Ltd. en
dc.rights © Draper et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. en
dc.rights.uri http://​creativecommons.​org/​licenses/​by/​2.​0 en
dc.subject Antimicrobial en
dc.subject Synergy en
dc.subject Lantibiotic en
dc.subject Bacteriocin en
dc.subject Lacticin 3147 en
dc.subject Polymyxin en
dc.title The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteri en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Colin Hill, School of Microbiology, University College Cork, Cork, Ireland. +353-21-490-3000 Email: c.hill@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder Science Foundation Ireland en
dc.description.status Peer reviewed en
dc.identifier.journaltitle BMC Microbiology en
dc.internal.IRISemailaddress c.hill@ucc.ie en
dc.identifier.articleid 212


Files in this item

This item appears in the following Collection(s)

Show simple item record

© Draper et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Except where otherwise noted, this item's license is described as © Draper et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement